Delivery Order SPE2DB22D3010-SPE2DB25FP3NE
- Not listed
- The Defense Logistics Agency awarded a $1,768.44 delivery order to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count supply) under a firm fixed price contract type. The award was issued on June 2, 2025, with an ultimate completion date of June 3, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location. This delivery order is a child contract under...
- The Defense Logistics Agency awarded a $3,536.88 delivery order to AmerisourceBergen Drug Corp for XCOPRI 25 mg tablets (30-count units) with a firm fixed price structure. The contract, which was competitively awarded without set-aside designation, is scheduled for completion by June 2, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $1,877.45 delivery order to AmerisourceBergen Drug Corp for XCOPRI 200 mg tablets (30-count units) on June 16, 2025, with a completion date of June 17, 2025. This firm fixed-price, competitively awarded delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XCOPRI 100 mg tablets (30-count) on May 20, 2025, with a ceiling value of $1,979.46 under a firm fixed-price contract type. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was made through open competition with no set-aside designation,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,794.10 to AmerisourceBergen Drug Corp for XCOPRI 150 mg tablets (30-count supply) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion global pharmaceutical support vehicle running...
- The Defense Logistics Agency awarded a delivery order valued at $3,219.60 to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count units) with an ultimate completion date of August 28, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor headquartered in Conshohocken, Pennsylvania. The contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $1,178.96 to AmerisourceBergen Drug Corp for XCOPRI 25 mg tablets (30-count package). The contract, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, represents a firm fixed-price delivery order with no set-aside designation. The work will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XCOPRI 150 MG tablets (30-count units) with a ceiling value of $1,830.53. This firm fixed-price delivery order, awarded on August 15, 2025, with an ultimate completion date of August 18, 2025, represents a non-competitive, non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. The delivery order is a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count) with a ceiling value of $1,786.08. This firm fixed-price delivery order, issued on April 24, 2025, with a completion date of April 25, 2025, was competitively awarded without set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,768.44 for XCOPRI 150 mg tablets (30-count units) with an ultimate completion date of July 24, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and will be performed at the company's corporate office in Conshohocken, Pennsylvania. The award leverages AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical, a...
- SPE2DB22D3010Indefinite Delivery Contract
- SPE2DB22D3010-SPE2DB25FP3NEDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,874.46 to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count supply) under a firm fixed-price contract. The award was made on September 17, 2025, with an ultimate completion date of September 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. No set-aside designation was applied to this award, indicating it was competitively awarded through open procurement procedures. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement needs across military and veteran healthcare systems. The company's extensive portfolio of federal contract awards with the DLA and its Medical Supply Chain demonstrates its capability to supply a comprehensive range of pharmaceutical products, including brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. This particular delivery order for XCOPRI—an anticonvulsant medication—aligns with the company's established role in supporting the Defense Health Agency and other government healthcare systems through flexible contract vehicles designed to meet diverse military medical supply requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 9/17/25 |